LCTX Lineage Cell Therapeutics, Inc.: institutional ownership and insider trading
145 funds reported holding $168M of Lineage Cell Therapeutics, Inc. in their latest 13F filings; in Q2 2026 funds net sold $497K, with 33 new positions and 33 funds selling out; over the last 12 months insiders bought $24.5K and sold $0 on the open market.
Famous investors holding LCTX
- Izzy Englander (Millennium Management): $3.95M, 0.0% of the portfolio
- Renaissance Technologies (Renaissance Technologies): $1.76M, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $610K, 0.0% of the portfolio
- Two Sigma (Two Sigma Investments): $72.0K, 0.0% of the portfolio
Largest institutional holders of LCTX
- BROADWOOD CAPITAL INC — $64.9M
- BlackRock, Inc. (BLK) — $17.3M
- VANGUARD GROUP INC — $16.1M
- VANGUARD CAPITAL MANAGEMENT LLC — $11.9M
- COMERICA BANK — $7.68M
- GEODE CAPITAL MANAGEMENT, LLC — $6.94M
- Defender Capital, LLC. — $6.35M
- FIFTH THIRD BANCORP (FITB, FITBI, FITBO, FITBP) — $6.03M
- MILLENNIUM MANAGEMENT LLC — $3.95M
- STATE STREET CORP (STT, STT-PG) — $3.03M
Recent LCTX insider trades
- Mar 12, 2026: Culley Brian M bought 15,000 shares ($24.5K)
- Jan 27, 2025: Broadwood Partners, L.P. bought 7,894,737 shares ($6.00M)
- Nov 26, 2024: Howe Jill Ann bought 15,000 shares ($8.85K)
- Nov 26, 2024: Samuel George A. III bought 15,000 shares ($9.00K)
5%+ owners
- BlackRock, Inc.: 5.3% (Schedule 13G, filed Jul 29, 2026)